Cargando…

Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories

BACKGROUND: Mutations in the KRAS gene are associated with poor response to epidermal growth factor receptor inhibitors used in the treatment of metastatic colorectal cancer. Factors influencing KRAS test results in tumor specimens include: tumor heterogeneity, sample handling, slide preparation, te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feigelson, Heather Spencer, Goddard, Katrina AB, Johnson, Monique A, Funk, Kellyan C, Rahm, Alanna Kulchak, Kauffman, Tia L, Chitale, Dhananjay A, Le Marchand, Loic, Richards, C Sue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441241/ https://www.ncbi.nlm.nih.gov/pubmed/22534075 http://dx.doi.org/10.1186/1756-0500-5-196

Ejemplares similares

Oncologists' attitudes toward KRAS testing: a multisite study
por: Harris, Julie N, et al.
Publicado: (2013)

Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample
por: Feigelson, Heather Spencer, et al.
Publicado: (2014)

Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy
por: Webber, Elizabeth M, et al.
Publicado: (2015)

Alternate Service Delivery Models in Cancer Genetic Counseling: A Mini-Review
por: Buchanan, Adam Hudson, et al.
Publicado: (2016)

Evaluating cancer genetic services in a safety net system: overcoming barriers for a lasting impact beyond the CHARM research project
por: Okuyama, Sonia, et al.
Publicado: (2023)

Design of a randomized controlled trial for genomic carrier screening in healthy patients seeking preconception genetic testing
por: Kauffman, Tia L., et al.
Publicado: (2016)

Barriers, facilitators, and solutions to familial hypercholesterolemia treatment
por: Jones, Laney K., et al.
Publicado: (2020)

Identifying patients with Lynch syndrome using a universal tumor screening program in an integrated healthcare system
por: Crain, Philip R., et al.
Publicado: (2022)

Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system
por: Muessig, Kristin R., et al.
Publicado: (2022)

Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing
por: Himes, Patricia, et al.
Publicado: (2017)

Generation and Implementation of a Patient-Centered and Patient-Facing Genomic Test Report in the EHR
por: Goehringer, Jessica M., et al.
Publicado: (2018)

Adaptation and early implementation of the PREdiction model for gene mutations (PREMM(5)™) for lynch syndrome risk assessment in a diverse population
por: Mittendorf, Kathleen F., et al.
Publicado: (2021)

Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study
por: Guo, Boya, et al.
Publicado: (2023)

Developing Pharmacogenomic Reports: Insights from Patients and Clinicians
por: Jones, Laney K., et al.
Publicado: (2018)

Enhancing genomic laboratory reports from the patients' view: A qualitative analysis
por: Stuckey, Heather, et al.
Publicado: (2015)

Enhancing genomic laboratory reports: A qualitative analysis of provider review
por: Williams, Janet L., et al.
Publicado: (2016)

Impact of a Patient-Facing Enhanced Genomic Results Report to Improve Understanding, Engagement, and Communication
por: Williams, Janet L., et al.
Publicado: (2017)

Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis
por: Jones, Laney K., et al.
Publicado: (2021)

It’s complicated: criteria for policy decisions for the clinical integration of genome-scale sequencing for reproductive decision making
por: Wilfond, Benjamin S, et al.
Publicado: (2015)

A mainstreaming oncogenomics model: improving the identification of Lynch syndrome
por: O’Shea, Rosie, et al.
Publicado: (2023)

Estimating haplotype frequencies in pooled DNA samples when there is genotyping error
por: Quade, Shannon RE, et al.
Publicado: (2005)

Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens
por: Loudig, Olivier, et al.
Publicado: (2017)

Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study
por: Rohan, Thomas E, et al.
Publicado: (2021)

Understanding the Patient Experience of Receiving Clinically Actionable Genetic Results from the MyCode Community Health Initiative, a Population-Based Genomic Screening Initiative
por: Baker, Anna, et al.
Publicado: (2022)

Economic Evaluation of Universal Lynch Syndrome Screening Protocols among Newly Diagnosed Patients with Colorectal Cancer
por: Hao, Jing, et al.
Publicado: (2021)

Assessment of willingness to pay for expanded carrier screening among women and couples undergoing preconception carrier screening
por: Clarke, Elizabeth V., et al.
Publicado: (2018)

The NextGen Study: patient motivation for participation in genome sequencing for carrier status
por: Kauffman, Tia L., et al.
Publicado: (2017)

Future possibilities in the prevention of breast cancer: Role of genetic variation in breast cancer prevention
por: Feigelson, Heather Spencer, et al.
Publicado: (2000)

User testing of a diagnostic decision support system with machine-assisted chart review to facilitate clinical genomic diagnosis
por: Kulchak Rahm, Alanna, et al.
Publicado: (2021)

The Healthcare Systems Research Network (HCSRN) as an Environment for Dissemination and Implementation Research: A Case Study of Developing a Multi-Site Research Study in Precision Medicine
por: Rahm, Alanna Kulchak, et al.
Publicado: (2019)

Time Costs for Genetic Counseling in Preconception Carrier Screening with Genome Sequencing
por: Lynch, Frances L., et al.
Publicado: (2018)

Stakeholder perspectives on implementing a universal lynch syndrome screening program: A qualitative study of early barriers and facilitators
por: Schneider, Jennifer L, et al.
Publicado: (2015)

Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program
por: Hao, Jing, et al.
Publicado: (2020)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

“Is It Worth Knowing?” Focus Group Participants’ Perceived Utility of Genomic Preconception Carrier Screening
por: Schneider, Jennifer L., et al.
Publicado: (2015)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

A case for expanding carrier testing to include actionable X‐linked disorders
por: Rope, Alan F., et al.
Publicado: (2018)

Survey of hepatitis E virus in pork products and pig stools in Nakhon Pathom Province, Thailand
por: Thippornchai, Narin, et al.
Publicado: (2022)

Integrating stakeholder feedback in translational genomics research: An ethnographic analysis of a study protocol’s evolution
por: Kraft, Stephanie A., et al.
Publicado: (2020)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Xu, Ke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g6vmo0u0h5f6kda0723t2lmlkq